24 HOUR WU ALLOCATION
| Research | Percent |
|---|---|
|
ANTIBODY DYNAMICS SIMULATION |
33.66% |
|
IL 2 RECEPTOR DYNAMICS |
16.83% |
|
ANTIBODY DYNAMICS |
13.86% |
|
IL 2 FORCE FIELD BENCHMARKING |
12.87% |
|
ANTIBODY AFFINITY MATURATION |
11.88% |
|
ALZHEIMERS |
5.94% |
|
ENZYME DYNAMICS |
4.95% |
7 DAY WU ALLOCATION
| Research | Percent |
|---|---|
|
ANTIBODY DYNAMICS SIMULATION |
17.25% |
|
ENZYME DYNAMICS |
17.11% |
|
ANTIBODY AFFINITY MATURATION |
13.46% |
|
ANTIBODY DYNAMICS |
11.92% |
|
IL 2 RECEPTOR DYNAMICS |
11.64% |
|
IL 2 FORCE FIELD BENCHMARKING |
11.22% |
|
ALZHEIMERS |
6.31% |
|
IL 2 DYNAMICS SIMULATIONS |
4.63% |
|
UNSPECIFIED |
2.81% |
|
STP6 SUGAR TRANSPORT |
2.1% |
|
SUCROSE TRANSPORT PLANTS |
1.54% |
12 WEEK WU ALLOCATION
| Research | Percent |
|---|---|
|
CANCER |
18.1% |
|
ANTIBODY DYNAMICS SIMULATION |
13.77% |
|
ANTIBODY DYNAMICS |
13.32% |
|
ANTIBODY AFFINITY MATURATION |
11.05% |
|
IL 2 FORCE FIELD BENCHMARKING |
10.94% |
|
ALZHEIMERS |
9.28% |
|
IL 2 RECEPTOR DYNAMICS |
7.7% |
|
IL 2 DYNAMICS SIMULATIONS |
5.73% |
|
ENZYME DYNAMICS |
4.87% |
|
IL 2 MOLECULAR DYNAMICS |
1.36% |
|
STP6 SUGAR TRANSPORT |
1.11% |
|
IL2 RECEPTOR DYNAMICS |
.95% |
|
SUCROSE TRANSPORT PLANTS |
.49% |
|
MEMBRANE TRANSPORT |
.44% |
|
ANTIBODY MATURATION SIMULATION |
.4% |
|
UNSPECIFIED |
.23% |
|
ATSTP10 SUCROSE TRANSPORT |
.18% |
|
PARKINSONS |
.09% |